

Application No. 10/528,974
Response Dated February 20, 2008
Reply to Office Action of November 20, 2007

Remarks/Arguments:

Claims 1-4 and 11 are pending in the instant application. Applicants have cancelled claims 5 to 10 as being directed to non-elected subject matter.

Response to Election/Restriction Requirement

Applicants thank the Examiner for agreeing to modify the restriction requirement of September 11, 2007 by including and examining the Group V invention (claim 11) with the elected Group I invention (claims 1-4).

Applicants note that they reserve the right to file divisional application(s) to the non-elected subject matter.

Obviousness-Type Double Patenting

The Examiner has rejected claims 1-4 and 11 over claims 1-2 and 12 of co-pending Application No. 10/528,612 (which has issued as U.S. Pat. No. 7,307,174 on December 11, 2007). In order to expedite prosecution of the instant application, Applicants submit herewith a terminal disclaimer, disclaiming the terminal part of the statutory term of any patent granted on the instant application beyond the expiration of U.S. Pat. No. 7,307,174.

Applicants believe the application is now in condition for allowance, which action is respectfully requested.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100835-1P US.

Respectfully submitted,

/John X. Haberman/

Name: John X. Haberman
Dated: February 20, 2008
Reg. No.: 55,236
Phone No.: 781-839-4736
Global Intellectual Property, Patents
AstraZeneca R&D Boston
35 Gatehouse Drive
Waltham, MA 02451